登录 | 注册    关注公众号  
微信公众号
搜索
>产品&服务 > CAR-T靶点蛋白

CAR-T靶点蛋白

荧光标记蛋白
CAR-T靶点蛋白
生物素标记蛋白
生物素标记蛋白
非标记蛋白
非标记蛋白

嵌合抗原受体T(CAR-T)细胞疗法是一种基于体外改造T细胞,使其表面表达特异性识别肿瘤表面抗原的受体片段的癌症免疫疗法,改造后的T细胞输入患者体内,不需要抗原递呈细胞(APC)的帮助,直接靶向体内癌细胞并发挥免疫杀伤作用。

对于CAR-T细胞来说,发挥肿瘤杀伤作用的有效成分是CAR阳性的T细胞,CAR-T细胞产品的包装规格及临床使用剂量是以CAR-T阳性细胞数表示的,因此,CAR转染阳性率是CAR-T质量控制的必检项,监管部门建议应采用流式细胞法检测CAR转染阳性率。目前有针对CAR不同结构区域的检测方法,包括针对CAR抗原结合位点的,比如CD19抗原,或针对轻链或铰链区的抗Fab抗体或Protein L蛋白,其中,针对抗原结合部位的CAR阳性率检测方法因其具有更好专属性而被广泛使用。

ACROBiosystems作为专注于医药研发领域的蛋白供应商,利用专业的蛋白研发平台、蛋白标记平台、稳定株开发平台和流式细胞分析平台,开发了一系列包括非标记、生物素标记、荧光标记等多种形式的CAR-T靶点蛋白以及配套的流式细胞法检测CAR阳性率的protocol,以助力CAR-T的研发,加速CAR-T研发的进程。目前产品已覆盖CD19、BCMA、CD22、MSLN和EGFR在内的近40个CAR-T热门靶点。

CAR-T阳性率检测策略及蛋白产品设计
直接检测法 —— 荧光标记蛋白
CAR-T靶点蛋白
产品特点
靶抗原预先标记了荧光素基团
可简化检测流程,节省检测时间
可避免因二抗交叉反应而引起的非特异性背景
> PE-labeled (点击分子即可查看产品详情)
> FITC-labeled (点击分子即可查看产品详情)
> 应用案例
使用FITC标记CD19蛋白检测Anti-CD19-CAR表达阳性率
CD19 CAR检测FACS 数据图
293 cells were transfected with anti-CD19-scFv and RFP tag. 2e5 of the cells were stained with B. FITC-labeled Human CD19 (20-291) (Cat. No. CD9-HF2H2, 10 µg/ml) and C. FITC-labeled protein control. A. Non-transfected 293 cells and C. FITC-labeled protein control were used as negative control. RFP was used to evaluate CAR (anti-CD19-scFv) expression and FITC was used to evaluate the binding activity of FITC-labeled Human CD19 (20-291) (Cat. No. CD9-HF2H2).
点击申请Protocol
点击联系我们

基于生物素-亲和素的检测法 —— 生物素标记蛋白

生物素标记蛋白
产品特点
靶抗原预先标记了生物素,随后可使用荧光标记的链霉亲和素检测
链霉亲和素对生物素具有极高的亲和力,两者的结合具有高度特异性
可高灵敏度和高特异性地检测CAR阳性表达率
> Biotinylated proteins -> Specially designed
CA125 Carbonic Anhydrase IX CD19 CD30 CD38 CD4 CD5 CD7 CD72 CD8 alpha CD8 alpha & beta CEACAM-5 Chimeric HLA-A*0201 (H-2Kb α3) & B2M & GP100(YLEPGPVTA) CLEC12A DLL1 DLL3 EGF R EGFRvIII EMMPRIN EpCAM EphA2 ErbB3 FAP FMC63 FOLR1 GUCY2C GUCY2D H-2Db & B2M H-2Kb & B2M & OVA (SIINFEKL) H-2Kb | B2M H-2Kd | B2M Her2 HLA-A*0101 & B2M HLA-A*0201 & B2M & CMV pp65 HLA-A*0201 & B2M & EBV LMP1 (YLLEMLWRL) HLA-A*0201 & B2M & EBV LMP2 (FLYALALLL) HLA-A*0201 & B2M & EBV LMP2A (CLGGLLTMV) HLA-A*0201 & B2M & HER2 (KIFGSLAFL) HLA-A*0201 & B2M & HER2 (LIAHNQVRQV) HLA-A*0201 & B2M & HPV (TIHDIILECV) HLA-A*0201 & B2M & HPV16-E7 HLA-A*0201 & B2M & KRAS (KLVVVGAGGV) HLA-A*0201 & B2M & KRASG12C (KLVVVGACGV) HLA-A*0201 & B2M & KRASG12D (KLVVVGADGV) HLA-A*0201 & B2M & KRASG12V (KLVVVGAVGV) HLA-A*0201 & B2M & KRASG12V (VVVGAVGVGK) HLA-A*0201 & B2M & MAGE-A10 (GLYDGMEHL) HLA-A*0201 & B2M & NY-ESO-1 (SLLMWITQV) HLA-A*0201 & B2M & p53 (HMTEVVRHC) HLA-A*0201 & B2M & p53 (HMTEVVRRC) HLA-A*0201 & B2M & PRAME (ALYVDSLFFL) HLA-A*0201 & B2M & PRAME (SLLQHLIGL) HLA-A*0201 & B2M & PSMA (MMNDQLMFL) HLA-A*0201 & B2M & Survivin (TLPPAWQPFL) HLA-A*0201 & B2M & Vaccinia virus (ILDDNLYKV) HLA-A*0201 & B2M & Vaccinia virus (ILYDNVVTL) HLA-A*0201 & B2M & Vaccinia virus (IMYDIINSV) HLA-A*0201 & B2M & Vaccinia virus (LLSYYVVYV) HLA-A*0201 & B2M & Vaccinia virus (SLSNLDFRL) HLA-A*0201 & B2M & Vaccinia virus (VLYNGVNYL) HLA-A*0201 & B2M & Vaccinia virus (YLAKLTALV) HLA-A*0201 | B2M & HIV Gag HLA-A*0201 | B2M & MAGE-A4 (KVLEHVVRV) HLA-A*0201 | B2M | AFP HLA-A*0201 | B2M | EW HLA-A*0201 | B2M | HBV HLA-A*0201 | B2M | MAGE-A1 HLA-A*0201 | B2M | MAGE-A2 HLA-A*0201 | B2M | MAGE-A3 HLA-A*0201 | B2M | MAGE-A4 HLA-A*0201 | B2M | p53 (GLAPPQHLIRV) HLA-A*0201 | B2M | p53 (RMPEAAPPV) HLA-A*0201 | B2M | RHAMM-R3 HLA-A*0206 & B2M HLA-A*02:01 & B2M HLA-A*02:01 & B2M & Glypican 3 HLA-A*02:01 & B2M & gp100 HLA-A*02:01 & B2M & NY-ESO-1 HLA-A*02:01 & B2M & WT-1 HLA-A*0301 & B2M HLA-A*0301 & B2M & gp100 (ALLAVGATK) HLA-A*0301 & B2M & KRAS (VVGAGGVGK) HLA-A*0301 & B2M & KRAS (VVVGAGGVGK) HLA-A*0301 & B2M & KRASG12C (VVGACGVGK) HLA-A*0301 & B2M & KRASG12C (VVVGACGVGK) HLA-A*0301 & B2M & KRASG12D (VVVGADGVGK) HLA-A*1101 & B2M & EBV (AVFDRKSDAK) HLA-A*1101 & B2M & EBV LMP2 (SSCSSCPLSK) HLA-A*1101 & B2M & HPV16-E7 (IVCPICSQK) HLA-A*1101 & B2M & KRAS (VVVGAGGVGK) HLA-A*1101 & B2M & KRASG12C (VVVGACGVGK) HLA-A*1101 & B2M & KRASG12D (VVVGADGVGK) HLA-A*1101 & B2M & KRASG12V (VVVGAVGVGK) HLA-A*1101 | B2M | KRAS (VVGAGGVGK) HLA-A*1101 | B2M | KRASG12D (VVGADGVGK) HLA-A*1101 | B2M | KRASG12V (VVGAVGVGK) HLA-A*11:01 & B2M HLA-A*2402 & B2M HLA-A*2402 & B2M & EBV EBNA3A (RYSIFFDYM) HLA-A*2402 & B2M & EBV EBNA3B (TYSAGIVQI) HLA-A*2402 & B2M & NY-ESO-1 (LLMWITQCF) HLA-A*2402 & B2M & p53 (TYSPALNKMF) HLA-A*2402 & B2M & Survivin-2B (AYACNTSTL) HLA-A*2402 & B2M & WT-1 (CYTWNQMNL) HLA-A*2601 & B2M HLA-A*3303 & B2M & EGF R(HVKITDFGR) HLA-A*3303 | B2M HLA-B*0702 & B2M HLA-B*0702 & B2M & HPV16 E7 (KPTLKEYVL) HLA-B*0801 & B2M HLA-B*1501 & B2M HLA-B*1502 & B2M HLA-B*2705 & B2M HLA-B*4001 & B2M HLA-B*5701 & B2M HLA-C*0303 | B2M HLA-C*0304 & B2M HLA-C*070201 & B2M HLA-C*0801 & B2M HLA-DRA1*0101 & HLA-DRB1*0401 HLA-DRA1*0101 & HLA-DRB1*1101 HLA-DRA1*0101 & HLA-DRB1*1101 & CLIP (PVSKMRMATPLLMQA) HLA-DRA1*0101 & HLA-DRB1*1101 & Influenza HA (PKYVKQNTLKLAT) HLA-E*0103 & B2M HLA-E*0103 & B2M & CMV UL40 (VMAPRTLLL) IL-13 R alpha 2 LILRB4 LY6G6D Mamu-A*01 & B2M Mamu-A*08 & B2M Mesothelin NCAM-1 Nectin-4 NKG2D Protein L PSCA ROBO1 ROR1 Siglec-2 Siglec-3 SLAMF7 Syndecan-1 TRBC1 VEGF R2
> 应用案例
使用生物素标记BCMA蛋白检测Anti-BCMA-CAR表达阳性率
BCMA  CAR检测FACS 数据图
Human T cells were transfected with anti-BCMA CAR and cultured for 3 days. Three days post-transfection, 1e6 cells were first incubated with 50 µl biotinylated human BCMA protein (Cat. No. BC7-H82F0, 8 µg/ml), washed and then stained with PE Streptavidin and analyzed by flow cytometry. (Data are kindly provided by PREGENE Biopharma)
点击申请Protocol
点击联系我们

间接检测法 —— 非标记蛋白

非标记蛋白
产品特点
靶抗原带有融合表位标签,随后可使用荧光标记的表位标签抗体作为二抗进行检测
可高灵敏度地检测CAR阳性表达率
有可能产生因二抗交叉反应引起的非特异性背景
> Unconjugated proteins -> Specially designed
> 应用案例
使用Human CD19, Fc Tag蛋白检测Anti-CD19-CAR表达阳性率
CD19(Fc Tag)CAR检测FACS 数据图
293 cells were transfected with FMC63-scFv and RFP tag. 2e5 of the cells were first stained with B. Human CD19 (20-291) Protein, Fc Tag, low endotoxin (Super affinity) (Cat. No. CD9-H5251, 3 µg/ml) and C. Human Fc Tag Protein Control, followed by FITC-conjugated Anti-human IgG Fc Antibody. A. Non-transfected 293 cells and C. Human Fc Tag Protein Control were used as negative control. RFP was used to evaluate CAR (anti-CD19-scFv) expression and FITC was used to evaluate the binding activity of Human CD19 (20-291) Protein, Fc Tag, low endotoxin (Super affinity) (Cat. No. CD9-H5251).
点击申请Protocol
点击联系我们
细胞级蛋白偶联磁珠
ACRO质量管理体系

消息提示

请输入您的联系方式,再点击提交!

确定